ArticleBMC biotechnology2025
Metabolomics-based analysis of the correlation between lipid metabolites and thyroid carcinoma.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Crosstalk between the microbiome and immune microenvironment in the pathogenesis and treatment of thyroid carcinoma: a narrative review.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundsThe pathogenesis of thyroid carcinoma (TC) involves various factors, with the interplay between hormonal and environmental influences being particularly critical. The gut microbiome, a long-overlooked risk factor, may play a significant role in TC development. Studies indicate that gut dysbiosis, bacterial outer membrane components such as lipopolysaccharide(LPS), and metabolites like Short-Chain Fatty Acids (SCFAs)and Trimethylamine N-Oxide (TMAO) are pivotal in mediating or influencing both gastrointestinal and extra-gastrointestinal tumors. Gut dysbiosis influences TC via microbial metabolites (e.g., LPS, SCFAs, TMAO) that modulate host immunity and steroid metabolism. However, reports on the multi-omics analysis of the correlation between gut microbiota, metabolites, and thyroid carcinoma remain scarce.
methodsThis study employs a case-control and cohort design, integrating 16 S rDNA sequencing, and metabolomics for multi-omics joint analysis of fecal samples from thyroid cancer patients before and after surgery. The aim was to identify associations between the gut microbiome, functional genes, and metabolites, as well as potential disease biomarkers.
resultsPostoperative samples showed significant lipid metabolite alterations (283 upregulated, 269 downregulated; P < 0.05).
conclusionsThis paper investigates the correlation between lipid metabolites and thyroid carcinoma through metabolomics-based analysis. Lipid metabolites, particularly cholesterol sulfate, are dysregulated in TC and linked to steroid/arachidonic acid pathways, suggesting potential diagnostic utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.